Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase II study of zandelisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma: ME-401-K02 study.
Munakata W, Kumode T, Goto H, Fukuhara N, Shimoyama T, Takeuchi M, Kawakita T, Kubo K, Sawa M, Uchida T, Mishima Y, Ichii M, Hanaya M, Matsumoto A, Kuriki M, Seike T, Izutsu K, Ishizawa K. Munakata W, et al. Among authors: kumode t. Br J Haematol. 2025 Jan 8. doi: 10.1111/bjh.19994. Online ahead of print. Br J Haematol. 2025. PMID: 39778876
Real-world effectiveness and safety of ibrutinib in patients with chronic lymphocytic leukemia in Japan: the Orbit study.
Muta T, Masamoto Y, Yamamoto G, Kurahashi S, Kameoka Y, Ota S, Matsuki E, Ozeki K, Toyama T, Takahashi N, Kumode T, Aotsuka N, Yoshimura T, Tamura H, Omi A, Shibayama K, Watanabe A, Isobe Y, Kojima K, Takizawa J, Nagai H, Suzumiya J, Aoki S. Muta T, et al. Among authors: kumode t. Int J Hematol. 2025 Feb;121(2):161-173. doi: 10.1007/s12185-024-03875-0. Epub 2024 Nov 26. Int J Hematol. 2025. PMID: 39586984 Free PMC article.
CD34+ and CD34- MM cells show different immune-checkpoint molecule expression profiles: high expression of CD112 and CD137 ligand on CD34+ MM cells.
Fukui-Morimoto A, Serizawa K, Fujimoto K, Hanamoto A, Iwata Y, Kakutani H, Kumode T, Hirase C, Morita Y, Tatsumi Y, Hanamoto H, Tanaka H, Matsumura I. Fukui-Morimoto A, et al. Among authors: kumode t. Int J Hematol. 2025 Jan;121(1):89-99. doi: 10.1007/s12185-024-03867-0. Epub 2024 Nov 12. Int J Hematol. 2025. PMID: 39531203 Free PMC article.
Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed/refractory diffuse large B-cell lymphoma.
Izutsu K, Kumode T, Yuda J, Nagai H, Mishima Y, Suehiro Y, Yamamoto K, Fujisaki T, Ishitsuka K, Ishizawa K, Ikezoe T, Nishikori M, Akahane D, Fujita J, Dinh M, Soong D, Noguchi H, Buchbjerg JK, Favaro E, Fukuhara N. Izutsu K, et al. Among authors: kumode t. Cancer Sci. 2023 Dec;114(12):4643-4653. doi: 10.1111/cas.15996. Epub 2023 Nov 3. Cancer Sci. 2023. PMID: 37921363 Free PMC article.
Long-term effectiveness and safety of high dose chemotherapy followed by autologous stem cell transplantation in daily practice in patients with diffuse large B-cell lymphoma.
Haeno T, Rai S, Miyake Y, Inoue M, Fujimoto K, Fujii A, Iwata Y, Minamoto S, Taniguchi T, Kakutani H, Inoue H, Kumode T, Serizawa K, Taniguchi Y, Hirase C, Morita Y, Tanaka H, Tatsumi Y, Ashida T, Matsumura I. Haeno T, et al. Among authors: kumode t. J Clin Exp Hematop. 2023 Jun 28;63(2):99-107. doi: 10.3960/jslrt.23001. Epub 2023 Apr 28. J Clin Exp Hematop. 2023. PMID: 37121716 Free PMC article.
Chlorpromazine cooperatively induces apoptosis with tyrosine kinase inhibitors in EGFR-mutated lung cancer cell lines and restores the sensitivity to gefitinib in T790M-harboring resistant cells.
Fujiwara R, Taniguchi Y, Rai S, Iwata Y, Fujii A, Fujimoto K, Kumode T, Serizawa K, Morita Y, Espinoza JL, Tanaka H, Hanamoto H, Matsumura I. Fujiwara R, et al. Among authors: kumode t. Biochem Biophys Res Commun. 2022 Oct 20;626:156-166. doi: 10.1016/j.bbrc.2022.08.010. Epub 2022 Aug 10. Biochem Biophys Res Commun. 2022. PMID: 35994825
28 results